济民药业,关爱无限 www.pidrug.com
香港济民药业微信二维码
198 9654 1773
当前位置:首页 > 药品资讯 > 精神科 > 依地普仑escitalopram

依地普仑escitalopram

[ 人气:181 | 日期: 2020-08-04 | 返回 | 打印 ]
依地普仑escitalopram
药品名称:依地普仑escitalopram
药品别名:依他普仑
英 文 名:escitalopram
药品价格:$ 美国市场售价 9.05 美元
研发公司:
适 用 症:用于严重的抑郁性障碍和一般焦虑症。
型号规格:本品为片剂,每片含有效成份5mg/10mg/20mg,每瓶100片装。
药品详情:

【依地普仑escitalopram 简述】
 
    依地普仑又名依他普仑,商品名Lexapro,本品是选择性5-羟色胺(5-HT)抑制剂,是抗抑郁药西酞普兰的衍生物(S-西酞普兰消旋体),通过对5-HT再摄取的抑制而起到增强中枢神经系统5-羟色胺能的活性。

依地普仑escitalopram_香港济民药业
 
【依地普仑escitalopram 适应症】
 
   依地普仑escitalopram用于严重的抑郁性障碍和一般焦虑症。
 
【依地普仑escitalopram 规格】
 
    本品为片剂,每片含有效成份5mg/10mg/20mg,每瓶100片装。
 
【依地普仑escitalopram 服用方法】
 
    口服,推荐剂量为每日10mg,如有必要,1周后可增至每日20mg。
 
【依地普仑escitalopram 注意事项】
 
    1.依地普仑与其他中枢神经药物同时使用时需谨慎。
 
    2.依地普仑与乙醇同时使用时需谨慎。
 
    3.室温保存(15~30℃)。
 
【依地普仑escitalopram 不良反应】
 
1.常见心悸、高血压;罕见心动过缓、心动过速、心电图异常、面色潮红、静脉曲张。
 
2.中枢和外周神经系统:常见偏头痛;罕见震颤、多动、眩晕、肌紧张亢进、不随意运动。
 
3.胃肠道:常见食欲增加、胃灼热、胃肠炎、腹部绞痛;罕见食管反流、胃胀气、腹泻、嗳气、吞咽困难、恶心、胃息肉、痔疮等。
 
4.全身性:常见过敏、面潮红、发热、肢痛、胸痛;罕见四肢浮肿、腿痛、寒战、晕厥。
 
5.血液和淋巴系统紊乱:罕见贫血、鼻出血、淋巴结病、血肿。
 
6.骨骼肌系统紊乱:常见关节痛、肌痛;罕见肌肉痛性痉挛、关节僵直、背不适。
 
7.代谢性紊乱:常见体重增加;罕见高血糖、体重减轻、口渴、胆红素增加、痛风、血胆红素增加。
 
8.精神系统紊乱:常见嗜睡;罕见精神过敏、恐惧、激动、健忘、神经质、抑郁、有自杀倾向、幻听。
 
9.生殖系统紊乱(女性):常见经期痉挛、经期紊乱;罕见月经过多、白带增加、乳房肿大、盆腔炎、经前期综合征。
 
10.呼吸系统:常见咳嗽、鼻窦充血、支气管炎;罕见哮喘、喉炎、气管炎、肺炎、气短。
 
11.皮肤:常见皮疹;罕见毛囊炎、斑秃、湿疹、瘙痒症、脂肪瘤。
 
12.感觉异常:常见视力模糊、耳鸣;罕见眼干、眼涩、味觉异常、结膜炎、视觉障碍、瞳孔放大。
 
13.泌尿系统:常见尿频、泌尿系统感染;罕见尿急、排尿困难、血尿、肾结石。

escitalopram

 
Escitalopram, sold under the brand names Cipralex and Lexapro among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.[2] Escitalopram is mainly used to treat major depressive disorder or generalized anxiety disorder.[2] It is taken by mouth.[2]
 
Common side effects include trouble sleeping, nausea, sexual problems, and feeling tired.[2]More serious side effects may include suicide in people under the age of 25.[2] It is unclear if use during pregnancy or breastfeeding is safe.[3] Escitalopram is the (S)-stereoisomer of the earlier medication citalopram, hence the name escitalopram.[2]
 
Escitalopram was approved for medical use in the United States in 2002.[2] In the United States the wholesale cost is about $2.04 per month as of 2017.[4] In the United Kingdom, as of 2018, non-proprietary escitalopram is around 1 / 20th as costly as the proprietary version.[5] Escitalopram is sometimes replaced by twice the dose of citalopram.[6] In 2016 it was the 26th most prescribed medication in the United States with more than 25 million prescriptions.[7]
 
Medical uses
 
Escitalopram has FDA approval for the treatment of major depressive disorder in adolescents and adults, and generalized anxiety disorder in adults.[2] In European countries and Australia, it is approved for depression (MDD) and anxiety disorders, these include: general anxiety disorder (GAD), social anxiety disorder (SAD), obsessive-compulsive disorder (OCD), and panic disorder with or without agoraphobia.
Depression
Escitalopram was approved by regulatory authorities for the treatment of major depressive disorder on the basis of four placebo controlled, double-blind trials, three of which demonstrated a statistical superiority over placebo.[8]
 
Controversy existed regarding the effectiveness of escitalopram compared to its predecessor citalopram. The importance of this issue followed from the greater cost of escitalopram relative to the generic mixture of isomers of citalopram, prior to the expiration of the escitalopram patent in 2012, which led to charges of evergreening. Accordingly, this issue has been examined in at least 10 different systematic reviews and meta analyses. As of 2012, reviews had concluded (with caveats in some cases) that escitalopram is modestly superior to citalopram in efficacy and tolerability.[9][10][11][12]
 
A 2011 review concluded that second-generation antidepressants appear equally effective, although they may differ in onset and side effects.[13] Treatment guidelines issued by the National Institute of Health and Clinical Excellence and by the American Psychiatric Association generally reflect this viewpoint.[14][15]
 
In 2018, a systematic review and network meta-analysis comparing the efficacy and acceptability of 21 antidepressant drugs showed escitalopram to be one of the most effective.[16]
Anxiety disorder
Escitalopram appears to be effective in treating general anxiety disorder, with relapse on escitalopram (20%) less than placebo (50%).[17]
Escitalopram appears effective in treating social anxiety disorder.[18]
Other
Escitalopram, as well as other SSRIs, are effective in reducing the symptoms of premenstrual syndrome, whether taken in the luteal phase only or continuously.[19] There are no good data available for escitalopram as treatment for seasonal affective disorder as of 2011.[20] SSRIs do not appear to be useful for preventing tension headaches or migraines.[21][22]
 
Overdose
 
Excessive doses of escitalopram usually cause relatively minor untoward effects, such as agitation and tachycardia. However, dyskinesia, hypertonia, and clonus may occur in some cases. Therapeutic blood levels of escitalopram are usually in the range of 20–80 μg/L but may reach 80–200 μg/L in the elderly, patients with hepatic dysfunction, those who are poor CYP2C19 metabolizers or following acute overdose. Monitoring of the drug in plasma or serum is generally accomplished using chromatographic methods. Chiral techniques are available to distinguish escitalopram from its racemate, citalopram.[41][42][43] Escitalopram seems to be less dangerous than citalopram in overdose and comparable to other SSRIs.[44]
 
Mechanism of action
 
Binding profile[45]
Site Ki (nM)
SERT 0.8-1.1
NET 7,800
DAT 27,400
5-HT1A >1,000
5-HT2A >1,000
5-HT2C 2,500
α1 3,900
α2 >1,000
D2 >1,000
H1 2,000
mACh 1,240
 
Escitalopram increases intrasynaptic levels of the neurotransmitter serotonin by blocking the reuptake of the neurotransmitter into the presynaptic neuron. Of the SSRIs currently on the market, escitalopram has the highest selectivity for the serotonin transporter (SERT) compared to the norepinephrine transporter (NET), making the side-effect profile relatively mild in comparison to less-selective SSRIs.[46]
 
Escitalopram is a substrate of P-glycoprotein and hence P-glycoprotein inhibitors such as verapamil and quinidine may improve its blood brain barrier penetrability.[47] In a preclinical study in rats combining escitalopram with a P-glycoprotein inhibitor, its antidepressant-like effects were enhanced.[47]
 
 



注:药品如有新包装,以新包装为准。以上资讯仅供医护人员内部讨论,不作任何用药依据,具体用药指引,请咨询主治医师。

更多相关资讯:返回顶部
最新药品资讯
  • Venclyxto(维奈妥拉)联合MabThera治疗慢淋白血病,患者死亡风险降低!
  • Tagrisso(Osimertinib)在英国获批用于两种肺癌适应症的治疗
  • ziritaxestat治疗弥漫性皮肤系统性硬化症(dcSSc)2期概念验证研究成功!
  • 美国FDA批准GSK三联疗法:可同时治疗哮喘和慢阻肺
  • NBIb-1817一次性治疗帕金森病(PD)显著改善运动功能、延长ON时间
  • 口服抗生素tebipenem HBr治疗cUTI和AP关键III期临床成功,疗效不劣于ertapenem
  • 下一代选择性免疫调节剂IMU-838治疗多发性硬化症(RRMS)具有显著疗效,有良好的安全性和耐受性!
  • Fintepla(芬氟拉明)口服溶液治疗Dravet综合征相关癫痫的第三项3期研究结果:抽搐发作显著减少
  • 视神经脊髓炎谱系障碍(NMOSD)创新药Enspryng(satralizumab)获美FDA批准
  • Fasenra与标准类固醇同时治疗鼻息肉三期临床结果积极
  • Darzalex Faspro申请新适应症,治疗轻链(AL)淀粉样变性!
  • 地诺单抗(Xgeva,denosumab)治疗实体瘤骨转移疗效怎样?
  • 新药IDH1抑制剂Tibsovo治疗胆管癌效果怎么样?
  • 拜耳Nubeqa(达罗他胺)治疗非转移性去势抵抗性前列腺癌显著延长患者生存!
  • FDA对罗氏Tecentriq治疗三阴性乳腺癌研究发出警告!
  • 加码多发性硬化症!罗氏启动三项临床试验研究
  • Xeglyze说明书-价格-功效与作用-副作用
  • 赛诺菲/再生元Dupixent(达必妥®)显著延缓哮喘患者肺功能下降:疗效维持3年!
  • 默沙东止咳药gefapixant2项关键III期临床试验成功:咳嗽频率显著降低
  • Ryplazim(纤溶酶原)再次申请上市:首个先天性纤溶酶原缺乏症(C-PLGD)治疗药物!
  • 拜耳Adempas用于经PDE5i治疗反应不足的肺动脉高压(PAH)患者IV期临床成功
  • Midostaurin(米哚妥林)适应症是什么?优势在哪里?
  • 艾普利Apixaban可以在哪里买到正品?
  • 维奈妥拉/维奈托克(VENETOCLAX)怎么服用?注意事项是什么?
  • 芦可替尼Ruxolitinib治疗特应性皮炎效果好不好?
  • 巯嘌呤片(6-MP)Puri-nethol治疗急性白血病效果如何?
  • 晚期HCC患者能从Ramucirumab中获益吗?
  • 赫赛汀+拉帕替尼治疗乳腺癌效果更好
  • 欧盟批准Imfinzi(英飞凡):一线治疗广泛期小细胞肺癌(ES-SCLC)!
  • 第三代强效COMT抑制剂Ongentys(opicapone)用于治疗帕金森病(PD)的新药在日本上市!


  • 如您发现本网站有文字编辑或内容错误,请点击此处发送(需要安装有foxmail或outlook支持),


    或发邮件至:info@morecare.hk,香港济民药业感谢您的到访!


    欢迎您添加香港济民药业微信,或在公众号内留言。

    香港济民微信公众号
    • 香港济民药业友情链接
    • 友情链接

    联系我们:

    地址:
    Rm. 314, Sun Ling Plaza, 30 On Kui Street, Fanling, HONG KONG
    邮箱:
    info@pidrug.com
    电话:
    198 9654 1773
    粤ICP备17150936号
    香港济民药业官方网站
    • 关注我们 :
    • 香港济民药业微博
    • 关注香港济民药业博客
    • 香港济民药业微信公众号